Article ; Online: The activation of spliced X-box binding protein 1 by isorhynchophylline therapy improves diabetic encephalopathy.
2023 Volume 39, Issue 6, Page(s) 2587–2613
Abstract: The primary symptom of diabetic encephalopathy (DE), a kind of central diabetic neuropathy caused by diabetes mellitus (DM), is cognitive impairment. In addition, the tetracyclic oxindole alkaloid isorhynchophylline (IRN) helps lessen cognitive ... ...
Abstract | The primary symptom of diabetic encephalopathy (DE), a kind of central diabetic neuropathy caused by diabetes mellitus (DM), is cognitive impairment. In addition, the tetracyclic oxindole alkaloid isorhynchophylline (IRN) helps lessen cognitive impairment. However, it is still unclear how IRN affects DM and DE and what mechanisms are involved. The effectiveness of IRN on brain insulin resistance was carefully examined in this work, both in vitro and in vivo. We found that IRN accelerates spliced form of X-box binding protein 1 (sXBP1) translocation into the nucleus under high glucose conditions in vitro. IRN also facilitates the nuclear association of pCREB with sXBP1 and the binding of regulatory subunits of phosphatidylinositol 3-kinase (PI3K) p85α or p85β with XBP1 to restore high glucose impairment. Also, IRN treatment improves high glucose-mediated impairment of insulin signaling, endoplasmic reticulum stress, and pyroptosis/apoptosis by depending on sXBP1 in vitro. In vivo studies suggested that IRN attenuates cognitive impairment, ameliorating peripheral insulin resistance, activating insulin signaling, inactivating activating transcription factor 6 (ATF6) and C/EBP homology protein (CHOP), and mitigating pyroptosis/apoptosis by stimulation of sXBP1 nuclear translocation in the brain. In summary, these data indicate that IRN contributes to maintaining insulin homeostasis by activating sXBP1 in the brain. Thus, IRN is a potent antidiabetic agent as well as an sXBP1 activator that has promising potential for the prevention or treatment of DE. |
---|---|
MeSH term(s) | Humans ; Oxindoles/pharmacology ; X-Box Binding Protein 1 ; Insulin Resistance ; Phosphatidylinositol 3-Kinases ; Endoplasmic Reticulum Stress ; Insulin ; Glucose ; Diabetes Mellitus/drug therapy |
Chemical Substances | rhyncophylline (46BQ79VJ8D) ; Oxindoles ; X-Box Binding Protein 1 ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Insulin ; Glucose (IY9XDZ35W2) |
Language | English |
Publishing date | 2023-01-25 |
Publishing country | Switzerland |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 48824-0 |
ISSN | 1573-6822 ; 0742-2091 |
ISSN (online) | 1573-6822 |
ISSN | 0742-2091 |
DOI | 10.1007/s10565-022-09789-z |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 3024: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.